애드바이오텍

179530KOSDAQ의약품 제조업

48.0 / 100

Reference Date: 2026-04-13

Financial Score9.0 / 40

News Sentiment15.0 / 25

Momentum12.0 / 20

Disclosure12.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Surged 66.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

AdvaTek is a biotech company developing eco-friendly products for livestock, aquaculture, and human use through technologies like IgY immune yolk antibodies, VHH nanobody antibodies, and microbial agents. Its IgY technology offers high titer and thermal stability, while VHH nanobodies provide strong tissue penetration and easy mass production, positioning them as promising alternatives to antibiotics and vaccines.

Number of Employees

64people

Average Salary

42.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 14.804.0Point

PBR

4.23Industry Average 1.040.0Point

4.1x industry avg (risky)

ROE

-40.31Industry Average 4.420.0Point

Well below industry avg

Debt Ratio

25.03Industry Average 11.980.0Point

2.1x industry avg (risky)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲11.1% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲14.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -70.2% (declining, 3yr)

Detailed News Sentiment

6 totalPositive 3Neutral 0Negative 0Average Sentiment Score 70

Positive
애드바이오텍, 19억원 규모 전환사채 만기 전 취득
애드바이오텍이 19억100만원 규모의 전환사채를 만기 전 취득하기로 결정하여 재무 안정성을 강화했다는 뉴스이다.
Positive
애드바이오텍, 여드름 완화 차세대 바이오 액티브 플랫폼 개발
애드바이오텍이 여드름 주요 원인균과 병원성 인자를 동시에 겨냥하는 차세대 바이오 액티브 플랫폼을 개발했다는 뉴스이다.
Positive
애드바이오텍, 지난해 감사의견 '적정'...재무 안정성 강화·성장 기반...
애드바이오텍이 2025년 재무제표에 대해 '적정' 감사의견을 받고 재무 안정성 강화 및 성장 기반 마련을 위해 노력하고 있다는 뉴스이다.

Detailed Momentum

52-week position5.0Point

52w mid range (48%)

Current 2,910Won52-week high 4,58552-week low 1,350

1-month return6.0Point

1m +66.57% (strong rise)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

12 totalPositive 1Neutral 11Negative 0

Neutral주식등의대량보유상황보고서(약식)2026-04-10
Positive[기재정정]주요사항보고서(유상증자결정)2026-04-10
Neutral상호변경안내2026-03-31
Neutral정기주주총회결과2026-03-31
Neutral주식등의대량보유상황보고서(약식)2026-03-27